Two tidbits...Two tidbits... Interesting TST has never mentioned sales revenue potential for Europe. Going back to Taylor Collison's report on Bioniche (Feb-11).... TC estimated and I quote" Peak sales (for Urocidin) in North America as US$310mil and Europe US$282 mil reached in 2021 (see page 6 of link below). Deal: with Ipsen for rights to Europe (and some other territories not mentioned but I assume minor potential) worth potentially US$137 million. Versus deal with Endo for "GLOBAL" rights at US$130 million (albeit Urocidin just completing ph3a at this stage). Nevertheless, Ipsen seem$ good at first glance. Royalty % not that clear at... "meaningful tiered double-digit royalties on net sales of MCNA". I recall similar type of descrip with Endo deal (albeit maybe suggesting beyond meaningful but that was pretty par-for-the-course back then). GLTA -- https://s3.amazonaws.com/zanran_storage/www.bioniche.com/ContentPages/2504158126.pdf